Company Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Why Investors Should Care
Generates a return on equity of 35.6%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.7%.
Revenue has grown at a 37.2% CAGR over the past five years.
Maintains a net profit margin of 19.3%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.66B (+15.6% YoY); net profit $836.30M.
- Trailing 12 Months Year-on-year growth — revenue +15.0%, earnings +92.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 37.2%, profit CAGR 8.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 37.17% |
| 1 Year: | 15.00% |
Compounded Profit Growth
| 5 Years: | 8.75% |
| 1 Year: | 92.20% |
Stock Price Performance
| 1 Year: | -13.14% |
| 6 Months: | +9.97% |
| 3 Months: | +17.43% |
| 1 Month: | -1.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.99 · Neutral
P/E of 31.81 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 35.6%.
- Healthy ROCE of 21.7%.
- Compounding revenue at 37.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DXCM DexCom, Inc. NDXSPX | 74.12 | 31.81 | $28.60B | 0.00% | 21.72% | 35.62% | 37.17% | 8.75% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 142.30M | 170.60M | 184.60M | 221.00M | 184.40M | 242.50M | 266.70M | 338.00M | 280.50M | 336.40M | 396.30M | 462.80M | 405.10M | 451.80M | 500.90M | 505.00M | 595.10M | 650.20M | 628.80M | 696.20M | 769.60M | 741.50M | 871.30M | 975.00M | 921.00M | 1.00B | 994.20M | 1.04B | 1.16B | 1.21B | 1.19B |
| Gross Profit | 59.40M | 46.50M | 66.00M | 74.70M | 91.20M | 75.10M | 85.50M | 101.10M | 116.70M | 94.10M | 117.50M | 127.00M | 153.50M | 118.90M | 153.60M | 168.60M | 222.80M | 168.80M | 206.50M | 246.90M | 309.30M | 256.50M | 284.10M | 340.40M | 343.90M | 417.10M | 446.90M | 398.10M | 449.50M | 494.20M | 462.60M | 546.40M | 623.30M | 561.90M | 626.70M | 593.80M | 589.00M | 688.80M | 731.40M | 750.30M |
| Operating Income | - | -12.70M | -3.60M | -42.40M | - | -19.20M | -20.10M | -18.50M | - | -40.40M | -13.60M | -500.00K | - | -30.70M | -4.90M | 13.90M | - | -14.40M | -800.00K | 56.00M | - | 33.60M | 67.80M | 94.10M | 45.90M | 101.00M | 118.30M | 41.30M | 77.00M | 147.50M | 47.20M | 128.10M | 205.50M | 101.10M | 158.00M | 152.00M | 133.70M | 212.60M | 242.50M | 255.30M |
| Net Income | 1.30M | -12.90M | -3.70M | -42.50M | 1.50M | -19.20M | -20.20M | -18.80M | -7.40M | -41.70M | 2.90M | -2.00M | -9.40M | -24.20M | 30.20M | 46.60M | -179.70M | -26.90M | -10.50M | 45.80M | 92.70M | 19.90M | 46.30M | 72.20M | 56.50M | 78.40M | 87.30M | 97.30M | 50.90M | 101.20M | 48.60M | 115.90M | 120.70M | 146.40M | 143.50M | 134.60M | 105.40M | 179.80M | 283.80M | 199.50M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.49 | 0.03 | -0.02 | -0.11 | -0.28 | 0.34 | 0.52 | -2.03 | -0.30 | -0.12 | 0.50 | 1.00 | 0.21 | 0.48 | 0.73 | 0.56 | 0.19 | 0.21 | 0.23 | 0.12 | 0.24 | 0.12 | 0.28 | 0.29 | 0.36 | 0.35 | 0.34 | 0.27 | 0.45 | 0.70 | 0.51 |
| R&D Expense | - | 19.80M | 24.40M | 64.80M | - | 32.20M | 36.30M | 43.90M | - | 48.10M | 45.30M | 43.30M | - | 44.80M | 47.20M | 50.10M | - | 59.00M | 69.00M | 66.70M | - | 73.10M | 79.90M | 87.70M | 109.40M | 129.10M | 128.80M | 135.90M | 121.70M | 110.30M | 119.00M | 119.30M | 131.40M | 141.50M | 136.00M | 135.40M | 145.20M | 148.20M | 157.50M | 145.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.69M | 48.60M | 76.30M | 99.90M | 160.00M | 259.20M | 402.00M | 573.30M | 718.50M | 1.03B | 1.48B | 1.93B | 2.45B | 2.91B | 3.62B | 4.03B | 4.66B |
| Gross Profit | 3.66M | 18.40M | 35.90M | 46.60M | 100.10M | 176.30M | 278.40M | 378.40M | 492.10M | 663.90M | 931.50M | 1.28B | 1.68B | 1.88B | 2.29B | 2.44B | 2.80B |
| Operating Income | -45.83M | -45.30M | -44.80M | -55.70M | -28.90M | -21.50M | -57.10M | -63.90M | -42.50M | -186.30M | 142.30M | 299.50M | 265.80M | 391.20M | 597.70M | 600.00M | 911.80M |
| Net Income | -53.52M | -55.20M | -44.70M | -54.50M | -29.80M | -22.40M | -57.60M | -65.60M | -50.20M | -127.10M | 101.10M | 549.70M | 216.90M | 341.20M | 541.50M | 576.20M | 836.30M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.58 | -1.44 | 1.10 | 1.33 | 0.53 | 0.82 | 1.30 | 1.42 | 2.09 |
| R&D Expense | 14.29M | 23.20M | 29.60M | 38.30M | 44.80M | 69.40M | 137.50M | 156.10M | 185.40M | 199.70M | 273.50M | 359.90M | 517.10M | 484.20M | 505.80M | 552.40M | 599.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 77.16M | 120.50M | 106.00M | 122.50M | 184.60M | 292.00M | 402.80M | 904.10M | 1.92B | 2.40B | 4.29B | - | 5.39B | 6.26B | 6.48B | 6.34B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.67B | 4.43B | 4.30B | 4.03B |
| Cash & Equivalents | 12.70M | 3.60M | 4.90M | 2.60M | 8.10M | 43.20M | 71.80M | 86.10M | 94.50M | 441.50M | 1.14B | 446.20M | 817.60M | - | 642.30M | 566.30M | 606.10M | 917.70M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 306.70M | 559.60M | 542.60M | 629.10M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 713.30M | 973.90M | 1.01B | 1.22B |
| Total Liabilities | - | - | 16.17M | 16.00M | 29.00M | 38.40M | 44.40M | 70.80M | 119.00M | 484.70M | 1.25B | 1.51B | 2.46B | - | 3.26B | 4.20B | 4.38B | 3.59B |
| Current Liabilities | - | - | 15.13M | 14.70M | 19.50M | 32.10M | 40.60M | 66.90M | 102.40M | 138.90M | 222.40M | 360.20M | 614.10M | - | 1.84B | 1.56B | 2.93B | 2.14B |
| Long Term Debt | - | - | - | - | 7.00M | 6.80M | 4.60M | - | - | - | - | - | - | - | 1.20B | 2.43B | 1.24B | 1.24B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.15B | 2.59B | 2.59B | 1.39B |
| Total Equity | -19.47M | -18.40M | 61.00M | 104.50M | 77.00M | 84.10M | 140.20M | 221.20M | 283.80M | 419.40M | 663.30M | 882.60M | 1.55B | - | 2.13B | 2.07B | 2.10B | 2.75B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 393.20M | 407.20M | 408.90M | 410.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -39.39M | -42.70M | -30.10M | -33.10M | 2.40M | 23.60M | 49.00M | 56.20M | 92.00M | 123.20M | 314.50M | 475.60M | 442.50M | 669.50M | 748.50M | 989.50M | 1.44B |
| Investing Cash Flow | -14.10M | -25.60M | -46.40M | 28.40M | 20.90M | -16.80M | -51.50M | -55.90M | -144.40M | -139.80M | -1.02B | -1.02B | -216.10M | -521.50M | -507.20M | -207.50M | 536.00M |
| Financing Cash Flow | 44.38M | 69.60M | 74.20M | 10.20M | 11.80M | 21.80M | 16.80M | 8.10M | 399.10M | 710.40M | 10.70M | 912.10M | 10.40M | -552.50M | -318.60M | -734.80M | -1.69B |
| Capital Expenditure | -2.99M | -6.90M | -8.00M | -9.50M | -7.90M | -16.20M | -33.30M | -55.70M | -66.00M | -67.10M | -180.00M | -199.00M | -389.20M | -364.80M | -236.60M | -358.80M | -363.50M |
| Free Cash Flow | -42.38M | -49.60M | -38.10M | -42.60M | -5.50M | 7.40M | 15.70M | 500.00K | 26.00M | 56.10M | 134.50M | 276.60M | 53.30M | 304.70M | 511.90M | 630.70M | 1.08B |
| Share Buybacks | - | - | - | - | - | - | - | 0 | 0 | 100.00M | 0 | 0 | 0 | 557.70M | 688.70M | 750.00M | 500.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 12.3% | 37.9% | 47.1% | 46.6% | 62.6% | 68.0% | 69.3% | 66.0% | 68.5% | 64.4% | 63.1% | 66.4% | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Operating Margin % | -154.4% | -93.2% | -58.7% | -55.8% | -18.1% | -8.3% | -14.2% | -11.1% | -5.9% | -18.1% | 9.6% | 15.5% | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Net Margin % | -180.3% | -113.6% | -58.6% | -54.6% | -18.6% | -8.6% | -14.3% | -11.4% | -7.0% | -12.3% | 6.8% | 28.5% | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
| ROE % | 290.9% | -90.5% | -42.8% | -70.8% | -35.4% | -16.0% | -26.0% | -23.1% | -12.0% | -19.2% | 11.5% | 35.4% | - | 16.0% | 26.2% | 27.4% | 30.5% |
| ROCE % | - | -73.0% | -42.3% | -64.4% | -32.0% | -14.9% | -25.4% | -21.3% | -5.6% | -11.0% | 7.0% | 8.1% | - | 11.0% | 12.7% | 16.9% | 21.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.10% | 38.96M | $2.76B |
| 2 | Vanguard Capital Management LLC | 6.48% | 25.02M | $1.77B |
| 3 | Vanguard Portfolio Management LLC | 4.98% | 19.22M | $1.36B |
| 4 | State Street Corporation | 4.65% | 17.93M | $1.27B |
| 5 | BAILLIE GIFFORD & CO | 4.04% | 15.60M | $1.10B |
| 6 | Alliancebernstein L.P. | 3.35% | 12.92M | $914.80M |
| 7 | Geode Capital Management, LLC | 3.20% | 12.35M | $873.96M |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.53% | 9.75M | $689.88M |
| 9 | Wellington Management Group, LLP | 2.42% | 9.33M | $660.16M |
| 10 | Amundi | 1.64% | 6.33M | $448.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DXCM
DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPeUNKV2hidmg3YzFDZ0s2bTN4dGhvbmhBWFVzZFFJZENadFhxdHVzTHQxQXZpcExfYkJLLVhNRS1pcTEyczY5SnZHYlpza0hqWVljVFBTWldmTkNfdFZqcDdUQmt1bFUzQmh5bnVpRURhOFJId3lHYlV2VDJQZXNoVE9seDU5dnNDM0t5NW…
Is DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNVk9VOWktdE9reHZhLXEwN2xfY2RKd21DQjRyUnFIbzJVOFVpOURZVERfb0F5eFlsQ2J2WkF6YkxtRGRIcFJubXZDN25BWWx5Y3R3RFhiMlhhQURuSXBGY3BUd0swMmRIS3pDXy1pa29DOFdZTG1tclZ2Y3g4TllYR3hOTzc4S083dUJHTm…
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYXBaa0Ytb2lMWXZDRjQ2b1Z2ek5fMEpmNjZ0SnMtc1pUWTR4YVRZT0JBVFJ4akhrT1YtWUpVUFhfV1FqNVZuWlRmWXVLVDhTcWVVM2dIWmhVVzhKMVRrOTRQM21ybVpwVkJOVGhYWV8yYkxoanBjcHFhcktsaDcxcUcwNUFMUmxfbzBRcU…
New 15.5‑day Dexcom glucose sensor authorized in Canada for adults - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQcTQ4ODJuRG1BRjJKM3VZMmZLbmlUTXRXV1JZZ09NMXFWZ2t3SFZyWC1hb1dsVS1yQUcyTkljenRMUlh0RnE5WTlNdzdPVl9iTWhEenh6UXI3UWRmWFR0VHNiMGlWeWNhM1hVdUpWNmF5RGZFVm9UNUNDWDE0cjduVFZuaXhLUUR1S2hNUU…
DexCom (DXCM) Revenue Breakdown - Main Composition - Moomoo
<a href="https://news.google.com/rss/articles/CBMijwNBVV95cUxNV2ZWQnF6MTZUZ3ZFUXdlTlpoZjRySEIxcnc1X2tyTnI3b29PZ2FSZFdJNFFWUEJlNENmS1NGbW1mYjcxNEVCWUlvb245YWpwZ0cxZVQtVHVldW4wNmZaX1NDcUxaWjlLR2ZvWmJ4cG9PNDFHdGd3eDlCZDEyTURacmZ4dVprRFVkdk9hRn…
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup - ChartMill
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQTnBRYnJpTWczdVpkeUFsMl84dTd6eDhBRmJFaklVaHdLaDB3c0t0R2lZdlRadWZEbDkxWk1pdmxDMU5vdTB0Tll0Y3VXSS1XUGxfNlNJMXJlY3lheHZfaXo5Wm9vZ2pzdU1SZ0xneUdjcWRJQWhoOFMxa1p4NGk4bWUxNy00LVp6UjJkVT…
DXCM — Frequently Asked Questions
What is the current share price of DexCom, Inc. (DXCM)?
As of 2026-07-14 21:23 PDT, DexCom, Inc. (DXCM) trades at $74.12 on NasdaqGS. Its 52-week range is $54.84 to $89.53.
What is the market capitalisation of DXCM?
DexCom, Inc. (DXCM) has a market capitalisation of $28.60B on NasdaqGS.
What is the P/E ratio of DXCM?
DXCM trades at a trailing price-to-earnings (P/E) ratio of 31.81. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 9.84.
What is the return on equity (ROE) of DXCM?
DXCM has a return on equity (ROE) of 35.62%. Its return on capital employed (ROCE) is 21.72%.
Is DXCM a good stock to buy?
This page provides a data-driven analysis of DexCom, Inc. (DXCM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.